image
Healthcare - Medical - Devices - NYSE - US
$ 23.09
-0.56 %
$ 986 M
Market Cap
-72.16
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AORT stock under the worst case scenario is HIDDEN Compared to the current market price of 23.1 USD, Artivion, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AORT stock under the base case scenario is HIDDEN Compared to the current market price of 23.1 USD, Artivion, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AORT stock under the best case scenario is HIDDEN Compared to the current market price of 23.1 USD, Artivion, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AORT

image
$32.0$32.0$31.0$31.0$30.0$30.0$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
389 M REVENUE
9.75%
38.9 M OPERATING INCOME
577.01%
-13.4 M NET INCOME
56.47%
22.2 M OPERATING CASH FLOW
18.12%
-28.2 M INVESTING CASH FLOW
-5515.14%
2.2 M FINANCING CASH FLOW
154.68%
97.3 M REVENUE
1.60%
2.67 M OPERATING INCOME
-39.16%
-16.5 M NET INCOME
0.00%
10.1 M OPERATING CASH FLOW
-29.05%
-11.4 M INVESTING CASH FLOW
61.23%
174 K FINANCING CASH FLOW
-98.35%
Balance Sheet Artivion, Inc.
image
Current Assets 290 M
Cash & Short-Term Investments 53.5 M
Receivables 85.9 M
Other Current Assets 151 M
Non-Current Assets 499 M
Long-Term Investments 0
PP&E 76.1 M
Other Non-Current Assets 423 M
6.78 %10.88 %19.10 %9.65 %53.59 %Total Assets$789.1m
Current Liabilities 66.8 M
Accounts Payable 18 M
Short-Term Debt 5.28 M
Other Current Liabilities 43.6 M
Non-Current Liabilities 446 M
Long-Term Debt 2.83 M
Other Non-Current Liabilities 443 M
3.50 %8.49 %86.42 %Total Liabilities$512.9m
EFFICIENCY
Earnings Waterfall Artivion, Inc.
image
Revenue 389 M
Cost Of Revenue 140 M
Gross Profit 249 M
Operating Expenses 210 M
Operating Income 38.9 M
Other Expenses 52.2 M
Net Income -13.4 M
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)389m(140m)249m(210m)39m(52m)(13m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
64.03% GROSS MARGIN
64.03%
10.01% OPERATING MARGIN
10.01%
-3.44% NET MARGIN
-3.44%
-4.84% ROE
-4.84%
-1.69% ROA
-1.69%
9.50% ROIC
9.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Artivion, Inc.
image
15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -13.4 M
Depreciation & Amortization 24.2 M
Capital Expenditures -11.2 M
Stock-Based Compensation 14.2 M
Change in Working Capital 0
Others -1.34 M
Free Cash Flow 11 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Artivion, Inc.
image
Wall Street analysts predict an average 1-year price target for AORT of $30.6 , with forecasts ranging from a low of $30 to a high of $33 .
AORT Lowest Price Target Wall Street Target
30 USD 29.93%
AORT Average Price Target Wall Street Target
30.6 USD 32.52%
AORT Highest Price Target Wall Street Target
33 USD 42.92%
Price
Max Price Target
Min Price Target
Average Price Target
343432323030282826262424222220201818May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.03 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.140.140.120.120.100.100.080.080.060.060.040.040.020.020.000.000.030.030.030.030.1220152015
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Artivion, Inc.
image
Sold
0-3 MONTHS
5.07 M USD 6
3-6 MONTHS
729 K USD 3
6-9 MONTHS
952 K USD 4
9-12 MONTHS
52.6 K USD 1
Bought
53.1 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. prnewswire.com - 1 month ago
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 1 month ago
Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. seekingalpha.com - 1 month ago
Artivion (AORT) Reports Break-Even Earnings for Q4 Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago. zacks.com - 1 month ago
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basis Achieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal year Adjusted EBITDA increased 15% to $17.6 million in the fourth quarter of 2024 compared to $15.3 million in the fourth quarter of 2023. prnewswire.com - 1 month ago
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com - 2 months ago
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks. None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. investors.com - 2 months ago
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation. prnewswire.com - 2 months ago
Best Momentum Stocks to Buy for January 7th NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024. zacks.com - 3 months ago
New Strong Buy Stocks for January 7th AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024. zacks.com - 3 months ago
US medical device giant Artivion says hackers stole files during cybersecurity incident Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident. techcrunch.com - 4 months ago
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. prnewswire.com - 4 months ago
8. Profile Summary

Artivion, Inc. AORT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 986 M
Dividend Yield 0.00%
Description Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Contact 1655 Roberts Boulevard N.W., Kennesaw, GA, 30144 https://artivion.com
IPO Date Feb. 12, 1993
Employees 1600
Officers Mr. James Patrick Mackin Chairman, President & Chief Executive Officer Dr. Robert C. Thomson Ph.D. Vice President of Research & Development Mr. Florian Tyrs Vice President of Global Operations